SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
FBLG

FibroBiologics, Inc. (NASDAQ:FBLG)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.70-$0.13 (-15.06%)
 
Market cap
$6.34M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 1, 2024
Market Cap$6.34M-86.4%
Revenue (ttm)$0
Net Income-$16.41M+11.3%
EPS-$3.78+60.6%
Shares Out8.99M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume49,626
Open$0.87
Previous Close$0.83
Day's Range$0.70 - $0.87
52-Week Range$0.62 - $9.60
Beta1.22
AnalystsBuy
Price Target$180.00(+25431.91%)
Earnings DateFeb 23, 2027
-14.46% (1D)
No price history available.

About FBLG

FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.

Address
455 East Medical Center Boulevard, Houston, TX, 77598, US
Market Cap
6 million
Employees
15
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$120.49K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From FBLG’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-15.06%
5 Days
-25.44%
1 Month
-30.88%
6 Months
-32.86%
1 Year
-86.44%

$FBLG stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in FBLG holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by FBLG's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

FBLG Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New FBLG patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to FBLG from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in FBLG

VXFVanguard Extended Market ETF$58.90K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from FBLG’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
61.81
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
65

News check: Company reporting Q3 results with upcoming catalysts and advancing fibroblast therapy platform; IP portfolio update signals ongoing development progress.

Recent Insider Activity

Buys
7
Sells
0
Buy Value
$120.49K
Distinct Buyers
4

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.